Patents by Inventor Smita Bhat

Smita Bhat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Selective subtype alpha 2 adrenergic agents and methods for use thereof
    Patent number: 8809379
    Abstract: The invention provides well-defined heterocyclic compounds that are useful as subtype selective alpha 2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with selective subtype modulation of alpha 2 adrenergic receptors.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: August 19, 2014
    Assignee: Allergan, Inc.
    Inventors: Todd M. Heidelbaugh, Ken Chow, Santosh C. Sinha, Phong X. Nguyen, Ling Li, Wenkui K. Fang, Janet A. Takeuchi, Smita Bhat
  • Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
    Patent number: 8735438
    Abstract: A compound having selective modulating activity at the alpha 2B and/or alpha 2C adrenergic receptor subtypes is represented by the general Formula 1: wherein n=1-4; X is C or N; R1-R6 can be the same or different and are independently selected from the group consisting of H, C1-6 alkyl, OCH3, OH, F, Cl, Br, CH2OH, CH2N(R7)2, C(O)R8, CH2CN, CF3, wherein R7 is H or C1-6 alkyl; and R8 is C1-6 alkyl or aryl. The compounds of Formula 1 can be incorporated in pharmaceutical compositions and used in methods of treatment of alpha 2 receptor mediated diseases and conditions.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: May 27, 2014
    Assignee: Allergan, Inc.
    Inventors: Santosh C. Sinha, Todd M. Heidelbaugh, Smita Bhat, Ken Chow, Michael Garst
  • Alkyne and alkene derivatives as sphingosine 1-phosphate-1 receptor modulators
    Patent number: 8541397
    Abstract: The present invention relates to novel alkyne and alkene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: September 24, 2013
    Assignee: Allergan, Inc.
    Inventors: Santosh C. Sinha, Smita Bhat, Evelyn Corpuz, Ken Chow, Wenkui K. Fang, Wha-Bin Im
  • Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds
    Patent number: 8309729
    Abstract: Disclosed herein are compounds represented by the structural formula: therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: November 13, 2012
    Assignee: Allergan, Inc.
    Inventors: Santosh C. Sinha, Smita Bhat, Ken Chow, Richard L. Beard, John E. Donello, Michael Garst
  • Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds
    Patent number: 8188279
    Abstract: Disclosed herein are compounds represented by the structural formula: therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: May 29, 2012
    Assignee: Allergan, Inc.
    Inventors: Santosh C. Sinha, Smita Bhat, Ken Chow, Richard L. Beard, John E. Donello, Michael Garst
  • THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS
    Publication number: 20110237797
    Abstract: Disclosed herein are compounds represented by the structural formula: therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Application
    Filed: June 1, 2011
    Publication date: September 29, 2011
    Applicant: ALLERGAN, INC.
    Inventors: Santosh C. Sinha, Smita Bhat, Ken Chow, Richard L. Beard, John E. Donello, Michael Garst
  • Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
    Patent number: 7638648
    Abstract: Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: December 29, 2009
    Assignee: Allergan Inc.
    Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok Yin Tsang, Ling Li, Janet A. Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Vidyasagar Vuligonda, Roshantha A. Chandraratna
  • SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF
    Publication number: 20090197898
    Abstract: The invention provides well-defined heterocyclic compounds that are useful as subtype selective alpha 2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with selective subtype modulation of alpha 2 adrenergic receptors.
    Type: Application
    Filed: January 14, 2009
    Publication date: August 6, 2009
    Inventors: Todd M. Heidelbaugh, Ken Chow, Santosh C. Sinha, Phong X. Nguyen, Ling Li, Wenkui K. Fang, Janet A. Takeuchi, Smita Bhat
  • Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors
    Patent number: 7476673
    Abstract: Compounds of the formula where the variables are as defined in the specification, are useful for preventing or treating emphysema and related pulmonary conditions of mammals and other diseases and conditions which are responsive to RAR? agonist retinoids, such as skin related diseases, including but not limited to acne and psoriasis.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: January 13, 2009
    Assignee: Allergan, Inc.
    Inventors: Kwok Yin Tsang, Santosh Sinha, Xiaoxia Liu, Smita Bhat, Roshantha A. Chandraratna
  • Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B
    Patent number: 7468391
    Abstract: The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: December 23, 2008
    Assignee: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Rong Yang, Liming Wang, Xiaoxia Liu, Kwok-Yin Tsang, Ling Li, Janet Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Roshantha A. Chandraratna
  • Disubstituted chalcone oximes having RAR? retinoid receptor antagonist activity
    Patent number: 7432388
    Abstract: Compounds of the formula where the variables have the values described in the specification are antagonists of RAR?retinoid receptors.
    Type: Grant
    Filed: June 4, 2007
    Date of Patent: October 7, 2008
    Assignee: Allergan, Inc.
    Inventors: Kwok Yin Tsang, Santosh Sinha, Xiaoxia Liu, Smita Bhat, Roshantha A. Chandraratna
  • Disubstituted chalcone oximes having RARgamma retinoid receptor antagonist activity
    Publication number: 20080097119
    Abstract: Compounds of the formula where the variables have the values described in the specification are antagonists of RAR?, retinoid receptors.
    Type: Application
    Filed: June 4, 2007
    Publication date: April 24, 2008
    Inventors: Kwok Tsang, Santosh Sinha, Xiaoxia Liu, Smita Bhat, Roshantha Chandraratna
  • Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
    Publication number: 20080004455
    Abstract: Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
    Type: Application
    Filed: March 23, 2007
    Publication date: January 3, 2008
    Applicant: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok Tsang, Ling Li, Janet Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Vidyasagar Vuligonda, Roshantha Chandraratna
  • Disubstituted chalcone oximes having RAR? retinoid receptor antagonist activity
    Patent number: 7253319
    Abstract: Compounds of the formula where the variables have the values described in the specification are antagonists of RAR? retinoid receptors.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: August 7, 2007
    Assignee: Allergan, Inc.
    Inventors: Kwok Yin Tsang, Santosh Sinha, Xiaoxia Liu, Smita Bhat, Roshantha A. Chandraratna
  • Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
    Patent number: 7226951
    Abstract: Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: June 5, 2007
    Assignee: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok Yin Tsang, Ling Li, Janet A. Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Vidyasagar Vuligonda, Roshantha A. Chandraratna
  • 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
    Patent number: 6936636
    Abstract: Compounds of the formula: where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of reducing serum thyroxine levels and transiently increasing triglyceride levels.
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: August 30, 2005
    Assignee: Allergan, Inc.
    Inventors: Santosh Sinha, Kwok Yin Tsang, Smita Bhat, Roshantha A. Chandraratna
  • Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B
    Publication number: 20050187298
    Abstract: The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.
    Type: Application
    Filed: December 13, 2004
    Publication date: August 25, 2005
    Applicant: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Rong Yang, Liming Wang, Xiaoxia Liu, Kwok-Yin Tsang, Ling Li, Janet Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Roshantha Chandraratna
  • Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
    Publication number: 20050176689
    Abstract: Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
    Type: Application
    Filed: December 16, 2004
    Publication date: August 11, 2005
    Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok Tsang, Ling Li, Janet Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Vidyasagar Vuligonda, Roshantha Chandraratna
  • Disubstituted chalcone oximes having RARy retinoid receptor antagonist activity
    Publication number: 20050165095
    Abstract: Compounds of the formula where the variables have the values described in the specification are antagonists of RAR? retinoid receptors.
    Type: Application
    Filed: December 23, 2004
    Publication date: July 28, 2005
    Inventors: Kwok Tsang, Santosh Sinha, Xiaoxia Liu, Smita Bhat, Roshantha Chandraratna
  • Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors
    Publication number: 20050148590
    Abstract: Compounds of the formula where the variables are as defined in the specification, are useful for preventing or treating emphysema and related pulmonary conditions of mammals and other diseases and conditions which are responsive to RAR? agonist retinoids, such as skin related diseases, including but not limited to acne and psoriasis.
    Type: Application
    Filed: December 17, 2004
    Publication date: July 7, 2005
    Inventors: Kwok Tsang, Santosh Sinha, Xiaoxia Liu, Smita Bhat, Roshantha Chandraratna